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Summary 
Infection with gram-negative and gram-positive bacteria remains a leading cause of death in patients 
with systemic lupus erythematosis (SLE), even in the absence of immunosuppresive  therapy. To 
elucidate the mechanisms that underly the increased risk of infection observed in patients with 
systemic autoimmunity, we have investigated host defense against bacterial infection in a murine 
model of autoimmunity, the MRL/Mp-lpr/lpr (MRL/Ipr) mouse. Our previous study implicated 
transforming growth factor ~ (TGF-/$) in a novel acquired defect in neutrophil function in MRL/lpr 
but not congenic MRL/Mp-+/+  (MR.L/n) mice (Gresham, H.D., C.J. Ray, and F.K. O'Sullivan. 
1991.j. Immunol.  146:3911.) We hypothesized from these observations that MRL/lpr mice would 
have defects in host defense against bacterial infection and that they would have constitutively 
higher local and systemic levels of active TGF-/~ which would be responsible, at least in part, 
for the defect in host defense. We show in this paper that spontaneous  elaboration  of active 
TGF-/$ adversely  affects  host defense  against both gram-negative and gram-positive  bacterial infection 
in MRL/1pr mice. Our data indicate that MRL/lpr mice, as compared with congenic MRL/n 
mice, exhibit decreased  survival in response to bacterial infection, that polymorphonuclear leukocytes 
(PMN) from MR1/lpr mice fail to migrate to the site of infection during the initial stages of 
infection, that MR.L/lpr mice have a significantly increased bacterial burden at the site of infection 
and at other tissue sites, and that this increased bacterial growth occurs at a time (>20 h after 
infection) when PMN influx is greatly enhanced in MRL/lpr mice. Most intriguingly, the alteration 
in PMN extravasation during the initial stages of infection and failure to restrict bacterial growth 
in vivo could be duplicated in MRL/n mice with a parenteral injection of active TGF-/51 at 
the time of bacterial challenge. Moreover, these alterations in host defense, including survival 
in  response  to  lethal  infection,  could be  ameliorated  in  MRL/lpr  mice by  the  parenteral 
administration of a monoclonal antibody that neutralizes the activity of TGF-fi. These data indicate 
that elaboration of TGF-fi as a result of autoimmune phenomenon suppresses host defense against 
bacterial infection and that such a mechanism could be responsible for the increased risk of bacterial 
infection  observed in patients  with autoimmune diseases. 
I 
nfection with gram-negative and gram-positive bacteria re- 
mains a leading cause of death in patients with systemic 
lupus erythematosus (SLE)  1 (1-4). However, the factors un- 
derlying the morbidity and mortality caused by local and sys- 
i Abbreviations used in this paper: EAE, experimental  autoimmune  enceph- 
alitis; KI+, E. coli KI+; MRL/Ipr, MIKL/Mp-Ipr/lpr; MRL/n, MRL/ 
Mp-+/+; RA, rheumatoid  arthritis; SA1, 8. aureaus SA1; SLE, systemic 
lupus erythematosis. 
temic infection observed in human autoimmune diseases are 
not well defined. Although this increased risk of infection 
has been attributed primarily to therapeutic immunosuppres- 
sion, lethal bacterial infection does occur in the absence of 
immunosuppressive therapy (1-3). In this regard, defects in 
neutrophil (PMN) function have been investigated as pos- 
sible contributors to infection in patients  with SLE (5-7). 
To elucidate the relationship of putative defects in PMN func- 
tion to the risk of infection in patients  with autoimmune 
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of systemic autoimmunity, the MRL/Mp-lpr/lpr (MRL/lpr) 
mouse (8-10).  Our previous work indicated that PMN from 
MRL/lpr mice, but not congenic MRL/Mp-+/+  (MRL/n) 
mice, exhibited defects in extravasation to a site of inflamma- 
tion and in amplification of phagocytic function (11). Our 
data implicated TGF-3 in the acquisition of these defects. 
From these observations, we hypothesized that MRL/lpr mice 
would have defects in host defense against bacterial infection 
and that they would have constitutively higher local or sys- 
temic levels of active  TGF-3 which would be responsible, 
at least in part,  for the defect in host defense. 
TGF-3 is a multifunctional cytokine with a regulatory role 
in a broad spectrum of biological processes (reviewed in 12). 
It is a vital bifunctional immune modulator, exhibiting both 
proinflammatory (12-14) and immunosuppressive properties 
(13). The immunosuppressive activities of TGF-3 have pro- 
vided the therapeutic basis for its use in the treatment of sev- 
eral nonspontaneous animal models of autoimmune disease, 
including  experimental  autoimmune  encephalitis  (EAE) 
(15-17),  streptococcal cell wall-induced arthritis (18), and 
collagen-induced arthritis (15). In fact, in vivo production 
of TGF-/~ may be responsible for the spontaneous resolution 
of EAE observed in some animals (19). In contrast to its ther- 
apeutic activity  in experimental autoimmune disease, mounting 
evidence in murine models of  leishmaniasis and trypanosomi- 
asis indicates that enhanced production of active TGF-B corre- 
lates strongly with susceptibility to infection (20, 21). In ad- 
dition, HIV infection induces elevated levels of  TGF-/~ which 
have been implicated in the immunosuppression observed in 
patients with AIDS (22,  23).  To date, no studies exist that 
have examined the effect of spontaneous production of active 
TGF-3, which may occur in human autoimmune diseases 
(24),  on the susceptibility to either gram-positive or gram- 
negative bacterial infection. 
Therefore, the purpose of the present work is to test our 
hypothesis that spontaneous elaboration of active TGF-3 in 
autoimmune MRL/lpr mice is causally related to an increased 
susceptibility to  bacterial  infection.  Here,  we  show  that 
MRL/lpr mice have a significantly increased  risk of lethal 
infection upon challenge with bacterial strains Escherichia coli 
KI+ (KI+) and Staphylococcus aureus SA1 (SA1) and that treat- 
ment  of  MRL/lpr  mice  with  anti-TGF-3  significantly 
ameliorates their host defense defect. These data suggest that 
use of TGF-3 antagonists in patients with autoimmune dis- 
eases may represent an important therapeutic modality for 
augmentation of host defense against infection with common 
bacterial  pathogens. 
Materials and Methods 
Mice.  MRL/Ipr and MRL/n mice  were obtained  originally  from 
The Jackson Laboratory (Bar Harbor, ME) and were bred and main- 
tained in microisolator housing units (Lab Products, Inc., May- 
wood, NJ) under specific pathogen-free  conditions. The pathogen- 
free status of  the colony was routinely monitored by complete  health 
surveillance including necrospy  examinations, appropriate cultures, 
and serologic studies by the Research Animal Diagnostic and In- 
vestigation Laboratory of the University of Missouri College of 
Veterinary  Medicine-Columbia  (Columbia, MO). The surveillance 
showed no evidence  of infection with naturally occurring murine 
pathogens, including Sendal virus and mouse hepatitis virus. 
Autoimmune  anti Host Defense Parameters.  Age-matched  male 
MRL/n and MRL/lpr mice were used in this study to avoid any 
influence  of gender on the host response to infection. The autoim- 
mune status and host defense status of 10- and 16-wk-old male 
MRL/n and MRL/lpr mice were assessed as follows: blood urea 
nitrogen  (BUN),  IgG antibodies to  double-stranded (ds)DNA 
by ELISA, and spleen weights as described (10); serum IgG levels 
by RID (The Binding Site, San Diego, CA), and serum C3 levels 
by RID (The Binding site). Sera to be tested were collected from 
five mice in  each group  by cardiac puncture  while under  the 
anesthetic effects of methoxyflurane (Pitman-Moore, Mundelein, 
IL). As has been observed in female MRL/lpr mice (10), serum 
IgG levels, spleen weights, and IgG antibodies to dsDNA were 
all significantly  higher in 10- and 16-wk-old male MRL/lpr mice 
than  in  age- and sex-matched MRL/n mice ~  <(0.01, Mann- 
Whitney test for nonparametrics). In contrast, the serum BUN 
and C3 levels were not significantly  different in 10- and 16-wk-old 
male MRL/lpr mice from those of age- and sex-matched  MRL/n 
mice and are generally not observed to be different until 20-24 
wk of age (8, 10) (data not shown). The percentage of granulo- 
cytes in the bone marrow of 12-wk-old male MRL/lpr and MRL/n 
mice was assessed by fluorescence flow cytometry. Femurs were 
removed aseptically  and flushed twice with HBSS (GIBCO BRL, 
Gaithersburg, MD) to obtain bone marrow leukocytes  (BML).  BML 
were stained by indirect immunofluorescence  as described (11) with 
rat IgG2b anti-mouse granulocyte Gr-1 (clone RB6-8C5; Phar- 
Mingen, San Diego, CA) or rat IgG2b as a control. Both MRL/n 
and MRL/lpr mice had equivalent numbers of  bone marrow gran- 
ulocytes (77.2 _+ 2.0 and 82.8 _+ 1.6%, respectively).  The majority 
of experiments were performed with 10-12-wk-old male mice. 
Microorganisms.  17.. coli O18:Kl:H7, strain Bort and E. coli xyl 
were obtained from Dr. A. S. Cross (Walter Reed Army Institute 
of Research, Washington, DC). S. aureus SA1 was obtained from 
Dr. J. Lee (Harvard University, Cambridge, MA) and S. aureus ST5, 
a microencapsulated strain was  obtained from D.  L.  Baddour 
(University of Tennessee, Knoxville, TN). Strains KI+  and SA1 
are pathogenic and both strains are encapsulated  (25-27). KI+ was 
grown in trypticase soy broth (Difco Laboratories, Detroit,  MI) 
overnight at 37~  and SA1 was grown on blood agar (Remel, 
Lenexa, KS) overnight  at 37~  The microorganisms  were suspended 
in pyrogen-free,  sterile normal saline (Kendall  McGaw, Irvine, CA) 
and adjusted to the desired  inoculum spectrophotometrically  at 530 
nm before injection. To maintain virulence, bacteria were passaged 
in an MRL/lpr mouse within 48 h before injection into the ex- 
perimental animals. 
Bacterial Challenge.  Mice  were injected either intraperitoneally 
or subcutaneously with bacteria that had been prepared as indi- 
cated. The inoculum used for bacterial challenge was confirmed 
by serial dilutions in sterile normal saline and each dilution was 
counted by a spread-plate method onto the appropriate agar media 
for the microorganism  used in the experiment. Once injected, mice 
were observed over a 14-d period and the results expressed as the 
percent of mice surviving the bacterial challenge. Statistical sig- 
nificance was evaluated using the Fisher's exact test. 
In addition to lethality, host susceptibility to bacterial infection 
was measured by examining viable bacterial counts in a lavage  of 
the peritoneum and in liver and spleen homogenates obtained at 
various time points after intraperitoneal bacterial challenge. Mice 
were killed  by cervical  dislocation  while under the anesthetic  effects 
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5 ml of sterile HBSS. Recovered lavage fluid from each mouse was 
serially diluted and aliquots of each dilution were spread-plated onto 
appropriate agar medium to obtain bacterial counts. Percentage and 
numbers of PMN/ml of peritoneal lavage were determined as de- 
scribed previously (11). After peritoneal lavage, the livers and spleens 
were resected and homogenized in sterile glass tissue grinders with 
1 ml of HBSS. An aliquot of each homogenate was serialty diluted 
and dilutions were spread-plated  onto appropriate media to obtain 
approximate bacterial counts. Statistical differences in bacterial CFU 
were determined by the Mann-Whitney U test for nonparametrics. 
TGF-fl Assay.  Splenic culture supernatants for assay of TGF-fl 
were generated as follows:  spleens from 10- and 16-wk-old  male 
MRL/n and MRL/lpr mice were removed aseptically, dispersed 
into media,  and washed with 10 mM EDTA to deplete platelets 
(28).  The  cells  were  suspended  in  RPMI  supplemented  with 
Nutridoma-SP (Boehringer Mannheim Corp., Indianapolis, IN) at 
107/ml and incubated in 24-well plates at 37~  in 5% CO2. After 
24 h, the cells were removed by centrifugation and the superna- 
tants assayed directly for measurement of active TGF-fl or acidified 
to measure total TGF-fl. Levels of active TGF-fl were measured 
in the peritoneal lavage samples generated after intraperitoneal chal- 
lenge with SA1. Lavage samples were centrifuged at 12,500 g for 
10 min and sterile-filtered before assessment of TGF-fl. TGF-B was 
measured with a bioassay using CCL64 mink lung cells (Amer- 
ican Type Culture Collection, Rockville, MD) (29). Briefly, sub- 
confluent CC1-64 cells were trypsinized and plated onto 96-well 
tissue  culture plates  at 5  x  104 cells/well in 100 #1 of DMEM 
medium supplemented with 10% FCS 10 mM Hepes, nonessen- 
tial amino acids, glutamine, and gentamycin. Cells were incubated 
at 37~  in 10% CO2 for 1 h to allow sufficient  time for cells to 
adhere. Experimental samples or TGF-fl standards diluted in com- 
plete DMEM without FCS were added in 100/zl aliquots to a final 
volume of 200/zl/wett. The mixtures were incubated at 37~  in 
10% CO2 for an additional 21 h after which the cells were pulsed 
with 0.5/zCi/well [3H]thymidine for 2 h, washed, and harvested 
onto filter disks for counting in a liquid scintillation counter (model 
LS6000IC,  Beckman Instruments, Palo Alto, CA). Growth inhi- 
bition was calculated as follows: percent growth inhibition =  100 
x  [1 -  (cpm sample/cpm control)], where cpm control represents 
baseline thymidine incorporation in the absence of added TGF-fl. 
Concentrations were obtained by comparison with a standard curve 
derived from purified human platelet TGF-fll (R & D  Systems, 
Inc., Minneapolis,  MN).  The data were analyzed by the Mann- 
Whitney test for nonparametrics. This assay predominately measures 
TGF-fl because treatment of splenic supernatants with either a poly- 
clonal rabbit IgG anti-TGF-fl (R. & D Systems, Inc.) or with a mono- 
clonal murine IgG1 anti-TGF-fl (Clone 1Dl1.16)  neutralized 75- 
80%  of the growth inhibiting activity. 
Treatment with TGF-fl and Anti-TGFfl.  Mice were under the 
anesthetic effects of methoxyflurane during the tail vein injections. 
Purified human platelet TGF-fll (R & D  Systems) was activated 
by reconstituting in sterile 4 mM HC1 containing 0.1% human 
serum albumin overnight at 4~  The activated TGF-fll was neu- 
tralized and adjusted  with sterile normal saline to 2/~g/ml. The 
vehicle control was normal saline which was treated in the same 
manner as the TGF-fll.  MRL/n mice were injected with 300 ng 
of active TGF-fll or vehicle control immediately before intraperi- 
toneal challenge with SA1. MRL/lpr mice were injected via the 
tail vein with 166/~g of murine IgG1 monoclonaI anti-TGF-fl, clone 
1Dl1.16, prepared as described (30), or routine IgG1 (The Binding 
Site) as a control, mAb 1Dl1.16 was able to neutralize murine TGF-fl 
assayed by the mink lung cell assay described above. Before injection, 
both antibodies were subjected to buffer exchange with pyrogen- 
free, sterile normal saline by dilution and concentration 3x  with 
Centricon-30 microconcentrators (Amicon Corp., Beverly, MA). 
The antibody concentration was adjusted to i  mg/ml and assayed 
for the presence ofendotoxin using an E-toxate Kit (Sigma Chem- 
ical Co., St. Louis, MO). The level of endotoxin was below 0.025 
IU/ml of injected material. Immediately after the antibody injec- 
tions, the mice were challenged intraperitoneally with SA1. 
Statistical Analysis.  Assistance  with  statistical  analyses  was 
provided by Dr. John Hewett (University of Missouri-Columbia, 
Columbia,  MO). 
Results 
MRL/Ipr Mice Are More Susceptible to the Lethal Effects of 
KI + and SA1  Than Are MRL/n Mice.  Our previous data 
indicated a novel acquired defect in PMN function in MILL/ 
lpr, but not congenic MRL/n mice (11).  We hypothesized 
that such a PMN defect would make these mice more sus- 
ceptible  to  infection.  To investigate  this  possibility,  male 
MRL/lpr and MRL/n mice were injected with either SA1 
or KI+. These bacterial strains are pathogenic for mice and 
rats (25-27) and infections with these organisms are repre- 
sentative of those observed in humans with defects in PMN 
function (31) and site SLE (1-3). Bacterial challenge was per- 
formed in male MRL/n and MRL/lpr mice at two different 
sites of injection (subcutaneous and intraperitoneal) and with 
different inocula (CFU) in 10-20-wk-old animals. After ob- 
servation for 14 d, the percentage of surviving animals was 
assessed. 
As  shown  in Fig.  1 A,  the survival of lO-wk-old male 
MR.L/n mice (100%) was significantly greater than age- and 
sex-matched MRL/Ipr mice (25%) after an intraperitoneal 
injection with 3.2  ￿  104 CFU of SA1 (p <0.005,  Fisher's 
exact test).  Similar results were obtained when  20-wk-old 
male mice were challenged intraperitoneally with 3.7  x  103 
CFU of SA1  (Fig.  1 B).  MRL/n  mice had  a  survival rate 
of 84% whereas MRL/lpr mice had a survival rate of 17% 
(Fig. 1 B; p <0.05). These data indicate that MRL/lpr mice 
have a significant risk of lethal infection as compared with 
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Figure  1.  Effect  of S. aureus SA1 injected i.p. on the survival of (A) 
10-wk-old male MRL/n (n  =  8) and MRL/lpr mice (n  =  8) and (B) 
20-wk-old male MRL/n (n =  6) and MRL/lpr mice (,  =  6). Animals 
were injected with 3.2  x  10~ CFU of SA1 (A) or 3.7  x  103 CFU (B). 
Survival is significantly  decreased for male MRL/1pr mice at both 10 wk 
(p <0.005, Fisher's exact test) and 20 wk of age (av <0.05, Fisher's exact test). 
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wk) when their renal function, complement component C3 
levels,  and  numbers  of granulocytes are  not  significantly 
different  from  age-  and  sex-matched  MRL/n  mice  (see 
Materials and Methods for discussion of these parameters). 
To demonstrate that an increased susceptibility of bacterial 
infection in MRL/lpr mice was not limited to gram-positive 
bacteria, we next investigated the effect of a gram negative 
bacteria, KI+, on the survival  of these murine strains.  As 
shown in Fig. 2 A, the survival of 10-wk-old MRL/n mice 
(100%) was significantly greater than age- and sex-matched 
MRL/Ipr mice (20%) after intraperitoneal injection of 2  x 
103 CFU of KI+  (p <0.05). Identical results were obtained 
when 1.2  x  104 CFU of KI+  was injected subcutaneously 
into 16-wk-old male mice (100%  survival  for MRL/n vs. 
0% survival for MRL/lpr, p <0.001, Fig.  2 B). These data 
indicate that MRL/Ipr mice, irrespective  of age, route of ad- 
ministration, or type of bacteria used, were significantly  more 
susceptible to lethal bacterial infection when compared with 
MRL/n mice. 
One possible explanation for these data could be that en- 
dotoxins or other bacterial products were primarily respon- 
sible for decreased survival of MRL/lpr mice rather than in- 
fection and colonization by the microorganism. To address 
this possibility, two other strains were tested in MRL/lpr 
and MRL/n mice. A nonencapsulated but LPS+ strain, E. coli 
xyl, was injected subcutaneously (6  x  104 CFU) into six 
MRL/n and six MRL/lpr mice. After 14 d, survival was 100% 
in both strains of mice (data not shown). In addition, S. aureus 
ST5, a microencapsulated strain, was injected intraperitoneally 
(107 CFU) into five mice from each strain. After 14 d, sur- 
vival was 100%  in both strains of mice (data not shown). 
These data suggest that the decreased  survival  observed  in 
MRL/lpr mice in Figs.  1 and 2 was due to the overall viru- 
lence of the bacteria and the host susceptibility to bacterial 
infection. 
Although the data in Figs. I and 2 reflect an increased risk 
of lethal infection in MRL/lpr mice as compared with MRL/n 
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Figure  2.  Effect  ofE. coli KI+ injected  intraperitoneally  (A) and sub- 
cutaneously  (B) on the survival  of (A) 10-wk-old male MRL/n (n = 6) 
and MRL/Ipr mice (n  =  5) and (B) 16-wk-old male MRL/n (n  = 6) 
and MRL/lpr mice (n = 5). Animals  were injected  with 2 x 103 CFU 
of KI+ (A) or 1.2  x  104 CFU (B). Survival is significantly  decreased 
for male MRL/lpr mice at both 10 wk (p <0.05, Fisher's exact test) and 
16 wk of age (p <0.001, Fisher's exact test). 
mice,  differences in survival between the two strains  were 
not observed at every concentration of CFU examined. For 
example, neither MRL/lpr nor MRL/n mice survived injec- 
tion of 106 or greater CFU of either KI+  or SA1 (data not 
shown). In addition, both MRL/n and MRL/lpr mice sur- 
vived injection with  102  CFU or  less of either microor- 
ganism. Thus, the increased risk of lethal infection observed 
in MRL/lpr mice is dependent on the concentration of mi- 
croorganism used to challenge the animals. 
Comparison of MRL/n and MRL/Ipr Mice  for Bacterial Burden 
and PMN Extravasation a  fier lntraperitoneal SA1 Challengr  Mor- 
tality after serious  infection is likely the result of complex 
events involving both the host response to the pathogen and 
the  ability of the microorganism to  evade host  defenses, 
proliferate,  and colonize beyond the initial site of infection. 
The decreased survival of the MRL/lpr mice in response to 
bacterial challenge could result from altered  host responses 
(i.e., overproduction of IL-1,  etc.) instead of the ability of 
the pathogen to evade host defenses and proliferate.  There- 
fore, to more precisely compare the risk of  bacterial infection 
in MRL/lpr and MRL/n mice, we evaluated over time the 
recovery of viable bacteria from the peritoneum as well as 
other tissue sites (liver and spleen) following intraperitoneal 
bacterial  challenge.  For these and subsequent experiments, 
10-12-wk-old male MRL/n and MRL/lpr mice were used. 
In addition, all subsequent bacterial  challenge experiments 
were performed with SA1 because it retained its pathogenic 
phenotype in propagative culture more reliably than the KI+ 
strain. 
When bacterial burden was assessed over 4 d after intra- 
peritoneal injection of SA1, MRL/n mice cleared the microor- 
ganisms within 48 h from the peritoneum, liver, and spleen. 
However, the MRL/lpr mice continued to have a large burden 
of bacteria  in the peritoneum, liver, and spleen (range:  104 
to  107 CFU) during this time period (Fig.  3).  These data 
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Figure  3.  Comparison  of MRL/n (open symbols) and MRL/lpr mice 
(solid symbols) for the recovery  for viable  bacteria 1-4 d after  intraperitoneal 
challenge  with 3.2 x 104 CFU of SA1. The data are depicted  as the log10 
CFU/ml of a 5-ml lavage of the peritoneal cavity (circles) or per ml of 
a 1 ml homogenate  of either the liver (triangles) or spleen (squares). MRL/n 
mice cleared  the bacterial  challenge  from  the lavage, liver, and spleen  within 
2 d whereas  the MRL/lpr mice  were  unable  to restrict the growth  of SA1. 
1696  TGF-fl  and Bacterial Infection  in Autoimmune  MRL/lpr Mice indicate that this microorganism was able to overcome host 
defenses in MRL/lpr mice, increase in number over the original 
inoculum injected,  and colonize not  only the peritoneum, 
but other organs as well. We conclude from these observa- 
tions that  MRL/1pr  mice were unable to adequately clear 
an infection  or contain  the infection  to a local site. 
Moreover, the results of these experiments indicated that 
the host's response within the first 24 h after bacterial chal- 
lenge was critical in the ability of MP,  L/n and MRL/1pr mice 
to survive. Therefore, we examined the bacterial burden in 
the peritoneal lavage 4 and 24 h  after intraperitoneal  chal- 
lenge with SA1. Because we observed previously that MRL/lpr 
PMN failed to extravasate  into thioglycollate stimulated peri- 
toneal  exudates  (11), we  also  assessed  the  percentage  and 
number of PMN in the peritoneal exudate. As shown in Fig. 
4 A, MRL/lpr PMN failed to extravasate into the peritoneum, 
as compared with MRL/n PMN, during the first 4 h after 
intraperitoneal bacterial challenge.  The differences between 
the two strains in percentage of PMN were reflected also in 
the numbers of PMN/ml of peritoneal lavage (Fig. 4 B). Both 
the percentage of PMN and the number of PMN/ml of la- 
vage were significantly lower in MP,  L/lpr mice (p <0.03 and 
p  <0.03,  respectively) (Fig.  4, A  and B).  In addition,  the 
total cell counts in the lavage were significantly lower in the 
MP,  L/lpr mice (data not shown). MP,  L/n mice had greater 
than three times the number of PMN in the peritoneal la- 
vage as did MRL/lpr mice. No significant differences in the 
recovery of viable bacteria from the peritoneal lavage were 
observed at  this  early time point.  (Fig.  4  C). 
It is important to note that 24 h after bacterial challenge, 
both the percentage and the number of PMN present in the 
peritoneal lavage of MP,  L/lpr mice had increased and was 
significantly  greater than the percentage and number of PMN 
present in MRL/n mice (p <0.002 andp <0.001, respectively) 
(Fig.  4, A  and B). In addition,  the total cell counts in the 
lavage were significantly higher in the MRL/lpr mice (data 
not  shown).  Therefore,  by 24 h,  the percentage  of PMN 
present in the peritoneum of MRL/lpr mice was continuing 
to increase at a time when the percentage of PMN present 
in the peritoneum of MRL/n mice was abating, consistent 
with a pattern of resolving inflammation (Fig, 4 A). In fact, 
the number of PMN/ml increased 35-fold in the MRL/lpr 
mice whereas it increased only 2.5-fold in MRL/n mice (Fig. 
4  B).  Moreover,  the  recovery of viable bacteria  from  the 
peritoneal  lavage 24  h  after  intraperitoneal  challenge  was 
significantly  different between the  two strains  (p <0.001) 
(Fig.  4 C).  The MP,  L/lpr mice had 44-fold more bacteria 
in the lavage than did the MRL/n mice. In addition, MRL/lpr 
mice had significantly greater numbers of CFU in the liver 
(p <0.002)  and  the  spleen  (p <0.04)  in  comparison  with 
MRL/n mice (data not shown).  Thus,  24 h  after the bac- 
terial challenge, the microorganisms were proliferating in the 
peritoneum of the MRL/1pr mice even though the percentage 
and number of PMN had increased.  Comparison of bacterial 
burden 4 and 24 h after intraperitoneal challenge shows that 
MRL/lpr mice are unable to restrict the growth of the micro- 
organism  over this 20-h period as compared with MRL/n 
mice (Fig. 4 C). These data demonstrate that MRL/lpr PMN 
are impaired in their ability to extravasate to a site of infec- 
tion during  the initial stages of infection and that  they are 
not able to adequately contain an infection once present at 
the site. 
MRL/Ipr Mice Exhibit Significantly Elevated  Levels of  Active 
and Total TGF-fl Compared  with MRL/n Mice.  Our previous 
data implicated TGF-/3 in the acquisition of the defective PMN 
function observed in MRL/lpr  mice (11). We investigated 
the spleen as a source of potentially activated cells with known 
capability for producing TGF-/3 (13) by assessing  the levels 
of both active and total TGF-B in supernatants  of platelet- 
depleted, resting spleen cell cultures from 10- and 16-wk-old 
male  MRL/n  and  MRL/Ipr  mice.  As  shown  in  Fig.  5, 
MRL/lpr mice released significantly higher levels of both active 
and total TGF-/3 in 24-h supernatants  of resting  spleen cell 
cultures as compared with MRL/n mice at both  10 wk (p 
<0.05 and p <0.05, respectively) and 16 wk of age ~  <0.05 
and p  <0.05,  respectively, Student's  t test).  Similar  results 
were obtained after 72 h of culture. These data demonstrate 
that unstimulated MRL/Ipr spleen cells produce elevated levels 
of active TGF-/3 and that this phenomenon increases in mag- 
nitude with  age. 
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Figure 4.  Comparison  of MRL/n and MRL/lpr 
mice for (A) percent PMN, (B) PMN number, and 
(C) log10 CFU/ml of a lavage of the peritoneal cavity 
and 4 and 24 h after intraperitoneal challenge with 
4.8  x  104 CFU of SA1. At 4 h, the percent PMN 
and PMN number/ml, but not the CFU/ml, were 
significantly different between MR1/n (n  =  4) and 
MRL/Ipr mice (n = 4) (p <0.03 and p <0.03, respec- 
tively, Mann-Whitney U test). At 24 h, the percent 
PMN, PMN number/m|, and the  CFU/ml were 
significantly different between  MRL/n (n = 13) and 
MRL/lpr mice (n  =  14) (p <0.002, p <0.001, and 
p  <0.001, respectively, Mann-Whitney U  test). 
MRL/lpr PMN are impaired in their ability to ex- 
travasate to a site of infection during the initial stages 
of infection (4 h) and they are not able to adequately 
restrict the growth of the microorganism once  present 
at the site, resulting in significantly  increased  bacterial 
burden. 
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Comparison of both active and total TGF-3 levels in 24-h 
resting spleen cell cultures from male MRL/n (n =  3) and MRL/lpr mice 
(n =  3). TGF-3 was measured by bioassay with mink lung cells. MRL/Ipr 
mice have significantly higher levels  of both active (p <0.05) and total TGF-3 
(p <0.05,  Mann-Whitney U  test)  at both  10 and  16 wk of age. 
We also investigated the levels of active TGF-B present in 
the peritoneal exudates of MRL/n and MRL/lpr mice 4, 24, 
and 48 h after intraperitoneal  SA1 challenge. At 4 h, TGF-3 
was not detectable in the peritoneal exudates of either strain. 
However, at 24 h MRL/lpr mice had greater concentrations 
of active TGF-3 in the peritoneum than did MRL/n mice 
but these levels were not significantly different (Fig. 6). In 
contrast, at 48 h the levels of active TGF-3 in MRL/lpr exu- 
dates  increased  significantly  over  those  of MRL/n  mice 
<0.03),  which were identical  to the concentrations ob- 
served  at  24  h  (Fig. 6).  These results  demonstrate that 
MRL/lpr mice had elevated levels of active TGF-3 at the site 
of infection and that these levels reach significance after the 
increase in bacterial burden and increase in PMN number. 
In addition, they suggest that spontaneous production of ac- 
tive TGF-3 may contribute to the increased risk of infection 
observed in MRL/lpr mice. 
Intravenous Injection of Active TGF-fll  into MRL/n Mice 
Mimics the Host Defense Defect Observed  in MRL/lpr Mice.  To 
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Figure  6.  Comparison  of active TGF-3 levels per ml of peritoneal la- 
vage from MKL/n and MKL/lpr mice 24 and 48 h after intraperitoneal 
challenge with 6  x  104 CFU of SA1. At 24 h,  levels of active TGF-3 
are not significantly different between MRL/n (n =  7) and MRL/lpr mice 
(n  =  6). However, at 48 h the levels are significantly different between 
MRL/n (n  =  9) and MRL/lpr mice (n  =  8) (p <0.03,  Mann-Whimey 
U  test). 
link  the elevated levels of active TGF-3 we  observed in 
MRL/lpr splenic supernatants with the increased risk of  bac- 
terial infection observed in these mice, we injected MRL/n 
mice parenterally with a single dose of active TGF-31 to de- 
termine whether we could mimic the response of MRL/lpr 
mice to bacterial challenge with SA1. If TGF-/~ had an effect 
on host susceptibility to bacterial infection in MRL/lpr mice, 
then treating MRL/n mice with TGF-31 should reproduce 
the responses observed in MRL/Ipr mice. Therefore we in- 
jected ll-wk-old male MRL/n mice with a single intrave- 
nous dose of either vehicle control or activated TGF-31 im- 
mediately before intraperitoneal  challenge with 8.5  x  104 
CFU of SA1. At 4 h after bacterial challenge, vehicle control- 
injected MRL/n mice had a significantly greater percentage 
and number of PMN in the peritoneal lavage than did the 
TGF-B-injected MRL/n mice ~ <0.02 andp <0.02, respec- 
tively) (Fig. 7, A and B). A decrease in the number and per- 
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Figure  7.  Comparison  of MRL/n injected 
via the tail vein with either 300 ng of active 
TGF-31 or vehicle control on the (A) percent 
PMN,  (B)  PMN  number,  and  (C)  log10 
CFU/ml of a lavage of the peritoneal  cavity 
4 and 24 h after intraperitoneal  challenge with 
8.5  x  104 CFU of SA1. At 4 h, the percent 
PMN  and  PMN  number/ml,  but  not  the 
CFU/ml, were significantly different between 
TGF-Bl-injected (n  =  4) and vehicle control- 
injected mice (n  =  5) ~  <0.02  and p <0.02, 
respectively, Mann-Whitney  U test). At 24 h, 
the percent PMN, PMN number/ml, and the 
CFU/ml were significantly different between 
TGF-fll-treated (n  =  t3) and control-treated 
mice (n  =  11)  (p <0.0002,  p  <0.0002,  and 
v <0.004, respectively,  Mann-Whitney U test). 
A  single injection of active TGF-~I into MRL/n mice at  the time of bacterial  challenge  duplicates both the alterations  in PMN extravasation  and 
the increased bacterial burden observed in MRL/lpr mice within the first  24 h of bacterial  infection. 
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31-treated MRL/n mice at 4 h after bacterial challenge mimics 
the response of MRL/lpr mice at the same time point. No 
differences between the two strains in the recovery of viable 
bacteria from the peritoneal lavage  were observed at this early 
time point (Fig. 7 C). 
At 24 h after bacterial challenge, both the percentage and 
number of PMN  present in  the peritoneal  exudate  were 
significantly higher in TGF-31-treated mice, mimicking the 
PMN response observed in MRL/Ipr mice at 24 h after chal- 
lenge (p <0.0002 andp <0.0002,  respectively) (Fig. 7, A and 
B). TGF-31-treated MRL/n mice also had significantly more 
bacteria in the peritoneal lavage than did the vehicle control- 
treated MRL/n mice (p <0.004) (Fig. 7 C). In addition, TGF- 
31-treated mice also had significantly higher numbers of  bac- 
teria  in the liver than  did control-treated mice (data not 
shown).  Comparison of bacterial burden in the peritoneal 
lavage 4 and 24 h after intraperitoneal  challenge shows that 
the TGF-31-injected animals  were unable  to  restrict  the 
growth of the microorganism over this 20-h period as com- 
pared with control-treated mice (Fig. 7 C). These observa- 
tions demonstrate that a single intravenous injection of ac- 
tive  TGF-31  into  MRL/n  mice at  the  time of bacterial 
challenge can duplicate both the alterations in PMN extrava- 
sation and the increased  bacterial burden observed  in MRL/lpr 
mice within the first 24 h after intraperitoneal challenge with 
SA1. 
Injection of Anti-TGF-fll  into MRL/Ipr Mice Significantly 
Ameliorates Their Defect in Host Defense against Bacterial Chal- 
lenge.  To further confirm our hypothesis that altered regu- 
lation of TGF-3 in MRL/lpr mice is affecting host response 
to bacterial infection, we assessed the effect of a single dose 
of mAb against TGF-3 injected intravenously into MRL/Ipr 
mice at the time of bacterial challenge. MRL/lpr mice were 
injected intravenously with 166/zg of either purified mono- 
clonal anti-TGF-3 or purified murine IgG1 as a control. Im- 
mediately after the injection of the anti-TGF-3 or control IgG, 
the mice were injected intraperitoneally  with 2.5-5  x  104 
CFU of SA1. 4 h after the bacterial challenge, the percent 
and number of PMN in the peritoneal lavage  were significantly 
elevated in the anti-TGF-3-treated mice as compared with 
those injected with control IgG1 (p <0.05,  for each, Fig. 8, 
A and B). At this time the bacterial burden in the peritoneal 
lavage was not significantly different (Fig. 8 C). 24 h after 
the bacterial challenge, the percent and number of PMN in 
the peritoneal lavage  were significantly lower in the anti-TGF- 
3-treated mice (p <0.003 and p <0.001,  respectively) (Fig. 
8, A  and B). The percent and number of PMN present in 
the anti-TGF-B-treated  MRL/Ipr mice were similar to the 
values observed in MRL/n mice for both 4 and 24 h after 
intraperitoneal  challenge with SA1 (Fig. 4, A  and B). Im- 
portantly, the anti-TGF-3-treated mice had significantly  fewer 
bacteria in the peritoneal lavage  as compared with the control- 
treated MRL/lpr mice (p <0.006)  (Fig. 8 C). In fact, treat- 
ment with anti-TGF-3 reduced the CFU in the peritoneal 
lavage from  6.05  _+  2.7  x  106/ml to  0.44  _+  0.13  x 
106/ml,  a  reduction  of  93%.  Therefore,  treatment  of 
MRL/lpr mice with anti-TGF-3 ameliorates their alteration 
in PMN extravasation into the peritoneum and decreases  their 
resulting  bacterial burden at that site. 
To determine whether the ability of anti-TGF-3 to reduce 
the CFU in the peritoneal lavage correlated with survival of 
MRL/lpr mice in response to SA1 challenge, we assessed the 
survival of control IgG1- and anti-TGF-/%treated MRL/lpr 
mice after intraperitoneal  challenge with 9  x  104 CFU of 
SA1. As shown in Fig. 9, the survival of MRL/1pr mice treated 
with 166/xg of anti-TGF-3 was significantly increased over 
the survival of control-treated mice (p <0.02).  These data 
indicate that the reduction of CFU in the peritoneal lavage 
observed with anti-TGF-B  treatment (Fig. 8 C) correlates 
with survival of MRL/Ipr mice after bacterial challenge. In 
conclusion, these data show that the failure of MRL/1pr mice 
to clear a bacterial infection and to contain the infection to 
a local site is due, at least in part, to the elaboration of active 
TGF-~. 
Discussion 
We show in this paper that spontaneous elaboration of ac- 
tive TGF-3 adversely affects host defense against both gram- 
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Figure  8.  Comparison  of MRL/lpr mice injected 
via the tail vein with either 166/xg of monoclonal 
routine IgG1 anti-TGF-3 (1Dl1.16) or control routine 
IgG1 on the (A) percent  PMN, (B) PMN number, 
and (C) log10 CFU/ml of a lavage of the peritoneal 
cavity 4 and 24 h after intraperitoneal  challenge with 
2.4-5.0  x  104 CFU of SA1. At 4 h the percent PMN 
and PMN number/ml, but not the CFU/ml, were 
significantly  different  between  anti-TGF-3-treated 
(n =  4) and control-treated  mice (n  =  4) (p <0.05 
for each, Mann-Whitney U  test).  At 24 h,  the per- 
cent PMN, PMN number/ml, and the CFU/ml were 
significantly  different  between  anti-TGF-3-treated 
(n =  13) and control-treated mice (n =  12) (p <0.003, 
p <0.001, andp <0.006,  respectively, Mann-Whitney 
U  test).  Treatment  of MRL/Ipr  mice  with  anti- 
TGF-3 ameliorates their alteration  in PMN extrava- 
sation into the peritoneum and decreases their resulting 
bacterial burden at  that  site. 
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Figure 9.  Effect  of S. aureus SA1 injected intraperitoneal on the sur- 
vival of 12-13-wk-old male MLR/lpr mice injected via the tail vein with 
either 166/zg of monoclonal murine IgG1 anti-TGF-/3 (1Dl1.16) (n  = 
9) or control murine IgG1 (n = 9). Animals were challenged  intraperitoneal 
with 9.0 x  104 CFU of gAl. Survival is significantly increased for male 
MRL/lpr mice treated with anti-TGF-/3 (p <0.02, Fisher's exact test). 
negative and gram-positive bacterial infection in MRL/lpr 
mice, a murine model of systemic autoimmune disease.  We 
derive this conclusion from the following data:  (a) MRL/lpr 
mice,  as  compared  with  congenic  MRL/n  mice,  exhibit 
elevated levels of active TGF-~ at the site of infection (Fig. 
6) and in  supernatants  of resting  spleen cell cultures  (Fig. 
5).  (b) PMN from MRL/lpr  mice, but not MRL/n mice, 
fail to migrate to the site of infection during the initial stages 
of infection (Fig.  3). (c) MRL/lpr mice have a significantly 
increased bacterial burden at the site of infection and at other 
tissue sites  24 h  after bacterial challenge as compared with 
MRL/n mice. Moreover, this increased bacterial burden occurs 
even though the percentage and number of PMN present at 
the site of infection are increased in MRL/lpr  mice (Figs. 
3 and 4).  (d) The  alteration  in PMN extravasation  during 
the initial stages of infection and the failure to restrict bac- 
terial growth in vivo could be duplicated in MRL/n mice 
with a parenteral injection of active TGF-/31  at the time of 
bacterial challenge (Fig.  7).  (e) The altercations in host de- 
fense  and  decreased  survival  in  response  to  infection  in 
MRL/lpr  mice could be ameliorated by the parenteral  ad- 
ministration of a mAb that neutralizes the activity of TGF-/8 
(Figs. 8 and 9). Thus, we believe that TGF-/~ induces a defect 
in host defense in MRL/lpr mice that contributes to their 
decreased survival in response to either gram-positive or gram- 
negative bacterial infection  (Figs.  1,  2,  and 9). 
These data extend our previous work where we examined 
PMN function in MRL/Ipr and MRL/n  mice (11). In that 
work, we showed that MRL/Ipr PMN had an acquired de- 
fect in amplification  of Fc receptor-mediated  phagocytosis 
and in extravasation  into a site of inflammation (thioglycollate- 
inflamed peritoneum).  Incubation of normal murine PMN 
in serum from MRL/1pr mice induced these defects and treat- 
ment of MRL/lpr serum with anti-TGF-/3 abrogated the in- 
duction of the PMN defects. In addition, incubation of normal 
PMN with purified TGF-fll induced identical defects in PMN 
function. Moreover, both MRL/lpr PMN and TGF-/31-treated 
MRL/n PMN regained normal function after incubation in 
tissue  culture  media  for  1-2  h  in  the  absence  of TGF-/3 
(Gresham, H., and F. O'Sullivan, unpublished observation). 
These data indicated that the novel defect in PMN function 
in MRL/lpr  mice was acquired and rapidly reversible and 
therefore, might be ameliorated by therapeutic intervention. 
TGF-~ is a potent immunosuppressive cytokine that has 
been implicated in the susceptibility to infection with intra- 
cellular pathogens such as Trypanosoma cruzi and Leishmania 
(21, 20). Macrophages infected with these microorganisms 
produce  active  TGF-/3,  which  in  turn  suppresses  normal 
cytokine-stimulated macrophage cytotoxic activity and allows 
for the permissive growth of these pathogens. Our study ex- 
tends these observations to include a role for TGF-/3 in the 
regulation of events within 24 h after infection with encap- 
sulated extracellular bacterial pathogens. Interestingly, these 
studies, like our own, demonstrate that active TGF-/3 given 
at the time of infection can convert nonsusceptible murine 
strains  into permissive environments  for the growth of the 
microorganism  and that  giving anti-TGF-B  at the time of 
infection provides protection to susceptible murine  strains. 
In fact, when we gave either TGF-/$ or anti-TGF-/3 24 h be- 
fore infection, there was no effect on the infectious process 
in the appropriate murine strain (Lowrance, J., and H. Gre- 
sham, unpublished observation). In total, these studies sug- 
gest that active TGF-/~ is involved in early events during in- 
fection  with  both  intracellular  parasites  and  extracellular 
bacteria. 
Encapsulated bacteria like E. coli and S. aureus use distinctly 
different mechanisms for invasion in vivo and for evasion of 
host defenses than do intracellular organisms like T. cruzi and 
Leishmania. Therefore,  the targets for the effects of TGF-/8 
are  likely to be different  in  these  two types of infectious 
processes.  In this regard, we believe that TGF-/3 is adversely 
affecting PMN function at two separate sites; once early in 
the infection by retarding PMN extravasation from the vas- 
culature and later by inhibiting normal bacteriostatic activity 
at the site of the infection.  The failure of MRL/lpr  PMN 
to extravasate into the peritoneum could be explained by an 
effect of TGF-/8 on the endothelium because TGF-fl treat- 
ment of endothelium reduces the adhesiveness of human PMN 
for the endothelial  surface (32).  In  addition,  disruption  of 
the TGF-fll gene creates TGF-/31-deficient  mice that die from 
an overwhelming multifocal inflammatory disease due to the 
unregulated infiltration of leukocytes into various tissues (33, 
34). These studies suggest that TGF-/$1  plays an important 
role in regulating leukocyte movement across the endothelium. 
Alternatively,  exposure to TGF-/81  in the vasculature may 
reduce the responsiveness of PMN  to chemotactic  stimuli 
generated at the site of infection. In this regard, intravenous 
administration of TGF-~I suppresses leukocyte recruitment 
to the inflamed synovium in SCW-induced arthritis in rats 
and anti-TGF-fl has a similar effect when injected intraartic- 
ularly (18,  35).  Because TGF-B1 is chemotactic for PMN, 
monocytes, and lymphocytes (36-39), one interpretation  of 
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gradient of TGF-31 established across the endothelium.  Be- 
cause we could see effects of TGF-31 on PMN extravasation 
within 1-2 h and much longer incubation times are required 
for the inhibitory effects of TGF-31 on endothelial-PMN adhe- 
sion (32), we are currently favoring the latter hypothesis to 
explain  our results. 
The mechanism by which TGF-B inhibits host defense at 
the site of infection cannot be explained currently.  Because 
our previous data demonstrated  TGF-3-induced  defects in 
PMN phagocytic function, one possibility to explain the de- 
creased clearance of the pathogen  from sites of infection is 
decreased phagocytic uptake of the organisms by PMN. How- 
ever, these organisms are not readily ingested by either normal 
PMN or macrophages,  consistent with the presence of the 
capsule (Gresham, H., unpublished observation). In addition, 
neither normal PMN nor macrophages have bactericidal ac- 
tivity in vitro for the encapsulated bacteria used in our studies, 
even in the presence of complement  (Lowrance, J.,  and H. 
Gresham,  unpublished  observation).  Therefore,  we believe 
that the effect of TGF-~ we observed on host defense is medi- 
ated by the suppression ofbacteriostatic activity in vivo (Fig. 
4 C). This is in contrast to the effect of TGF-3 on the cyto- 
toxic activity of macrophages against intracellular pathogens 
(20, 21). Thus, TGF-~ may adversely affect both bacteriostatic 
and bactericidal host defense mechanisms.  The precise bac- 
teriostatic mechanisms inhibited by TGF-B remain to be elu- 
cidated. Efforts are underway to develop an in vitro test of 
PMN function in which we can assess bacteriostatic para- 
meters. 
How our data relate to what is known about infection and 
PMN function in humans is also unclear.  It's intriguing  to 
speculate that  TGF-B-mediated suppression of PMN func- 
tion underlies the risk of bacterial infection and the defective 
PMN function observed in several human diseases, including 
diabetes mellitus (40, 41), AIDS (42, 43), and autoimmune 
diseases like SLE and rheumatoid arthritis (RA) (1-7, 44-46). 
Infections with common extracellular bacterial pathogens are 
significant causes of morbidity and mortality in all of these 
diseases  (1-4, 40, 42) and defects in PMN function similar 
to those we have observed in vitro and in vivo in MRL/lpr 
mice (11, and this paper) have been observed in patients with 
RA (44, 45), SLE (5-7),  diabetes mellitus (41),  and AIDS 
(43). Moreover, elevated TGF-3 has been detected, either sys- 
temically or at the site of inflammation, in each of these dis- 
eases. TGF-3 is elevated in the synovial fluid from patients 
with RA (46) and in the plasma of AIDS patients (22, 23, 
47). Cultured mononuclear cells from patients with SLE pro- 
duce increased levels of active TGF-3 as compared with normal 
controls  (24),  and TGF-3 is present  in the glomerulus  of 
kidneys from patients with type I diabetic nephropathy (48). 
Therefore, we believe that MRL/1pr mice may represent  a 
good model for elucidation of these host defense defects and 
for assessment of agents which augment host defense against 
bacterial infection. 
Studies are currently underway in our laboratories to de- 
termine the cellular source of the active TGF-3 produced in 
these mice and to determine the relationship of this TGF-3 
production to the autoimmune disease observed in MRL/lpr 
mice. We suspect that the elaboration of active TGF-3 during 
the course of an autoimmune disease may be a homeostatic 
mechanism for suppression of exaggerated and inappropriate 
immunostimulation.  Evidence for this comes from the fact 
that TGF-~ has been implicated in the spontaneous resolu- 
tion of murine EAE (19),  that TGF-31 suppresses autoanti- 
body levels in several murine models of autoimmunity,  in- 
cluding MRL/lpr (15-18, 49), and that  treatment  of these 
animals with anti-TGF-B increases their concentration of au- 
toantibodies (15, 16). Thus, some of the pathological sequelae 
observed in autoimmune diseases may develop as a consequence 
of this elaboration of TGF-3. In this regard, TGF-/~-medi- 
ated matrix deposition in the glomerulus appears to play a 
significant  role in decreased renal function observed in rat 
models of autoimmune glomerulonephritis  (48,  50) and in 
human type I diabetic nephropathy (48). Therefore, we pro- 
pose that an increased risk of infection is also a consequence 
of altered TGF-3 expression. It is intriguing to speculate that 
the use of TGF-3 antagonists  may represent  a rational  ap- 
proach for augmenting host defense against life-threatening 
infections in patients  with  autoimmune  diseases. 
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